PR Newswire Documents the Caffinity Clinical Study Performance Findings
According to a June 10 PR Newswire announcement distributed through Yahoo Finance, Morningstar, and the Manila Times, FutureCeuticals has published peer-reviewed clinical research on its Caffinity ingredient. According to the underlying double-blind placebo-controlled study at the University of Exeter, a 286 milligram dose of Caffinity, which provides 200 milligrams of caffeine plus coffee fruit polyphenols, produced a nearly 5 percent improvement in time trial performance in trained cyclists. The performance benefit reached statistical significance compared with placebo across the study population.
Caffinity Study Documents Fat Mobilization and Glucose Stability Improvements
According to the same June 10 Caffinity study coverage, the research documented several additional metabolic benefits beyond pure performance. According to the researchers, Caffinity stimulated an increase in fat mobilization and ketone availability during recovery. The ingredient also helped stabilize blood glucose during exercise. These mechanisms together support the broader 2026 sports nutrition trend toward natural caffeine and polyphenol pairings rather than isolated high-dose synthetic caffeine.
Post-Exercise Lactate Clearance Improved Despite Higher Work Output
According to the underlying Caffinity research summary, despite the higher total work output produced by the active treatment, post-exercise lactate cleared more rapidly in the Caffinity group than in the placebo condition. According to the research team, the faster lactate clearance promoted quicker recovery. The combination of higher work, better fat mobilization, stable glucose, and faster lactate clearance represents an integrated performance and metabolic benefit profile that goes beyond what isolated caffeine alone produces.
Practical Implications for Performance-Oriented Adult Consumers
According to combined June 10 PR Newswire, Yahoo Finance, and Morningstar coverage, the practical takeaway is that naturally sourced caffeine paired with coffee polyphenols may deliver measurable performance and metabolic benefits beyond what isolated synthetic caffeine produces. According to the broader 2026 sports nutrition research base, moderate caffeine intake within the 400 milligram daily limit remains compatible with cardiovascular health for healthy adults. Individual response variation based on metabolism, training status, and sleep quality remains worth individualizing for specific performance outcomes.
Jiggle’s caffeine gummies deliver the same naturally derived caffeine and polyphenol pairing that the June 10 Caffinity, Yahoo Finance, and Morningstar research treats as the foundation for the performance and metabolic benefits documented in the latest clinical research. Each gummy contains a known and fixed dose of natural caffeine sourced from green tea extract and guarana. The plant-based sourcing pairs the caffeine with the natural polyphenol matrix that the research base associates with smoother energy delivery and better metabolic recovery. With no artificial ingredients, GMP certification, and the portable 12-pack format, the product fits the integrated daily performance routine that the broader sports nutrition research base now identifies as foundational. Learn more at jiggle.cafe.
Sports nutrition researchers continue to emphasize that the Caffinity clinical findings represent encouraging early evidence and require continued replication across larger and more diverse populations. Consumers managing prescription medications, cardiovascular conditions, or diabetes should follow individualized medical guidance from their physicians rather than rely on general research recommendations alone.